 |
|
|
| |
ABT-072 or ABT-333 Combined With Pegylated Interferon/Ribavirin After 3-Day Monotherapy in HCV Genotype 1 (GT1)-Infected Treatment-Naïve Subjects: 12-Week Sustained Virologic Response (SVR12) and Safety Results
|
| |
| |
Reported by Jules Levin
EASL 2012 Apr 18-22 Barcelona Spain
Fred Poordad1, Eric Lawitz2, Edwin DeJesus3, Kris Kowdley4, Isabelle Gaultier5, Daniel Cohen5, Wangang Xie5, Lois Larsen5, Tami Pilot-Matias5, Gennadiy Koev5, Emily Dumas5, Thomas Podsadecki5, Barry Bernstein5
1Cedars-Sinai Medical Center, Los Angeles, California, United States; 2Alamo Medical Research, San Antonio, Texas, United States; 3Orlando Clinical Research Center, Orlando, Florida, United States; 4Digestive Disease Institute, Virginia Mason Medical Center, Seattle, Washington, United States;
5Abbott, Abbott Park, Illinois, United States
|
| |
|
|
|
|
|
